PARIS, FRANCE / ACCESSWIRE / October 18, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing ...
PARIS, FRANCE / ACCESSWIRE / September 12, 2022 / Pharnext SA (FR0011191287-ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for ...
Among the various subtypes of CMT, CMT1A is the most common form, characterized by a duplication of the PMP22 gene. Despite being a well-known genetic abnormality associated with CMT1A, the precise ...
At present, no known treatments are effective for neuropathy in Charcot-Marie-Tooth disease type 1A (CMT1A). In a transgenic mouse model of CMT1A, high-dosage ascorbic acid was associated with ...
Neucore Bio Inc. has received a $350,000 STTR phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the ...
Charcot-Marie-Tooth (CMT) disease is the most common inherited neurological disorder affecting peripheral motor and/or sensory nerves in humans. Monogenic disorders like CMT1A, CMT's most prevalent ...
A recent study by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the Uniformed Services University of the Health Sciences (USU), and a team of ...
19don MSN
이엔셀, CMT1A 임상 2a상 3개 기관 투여 본격화
[이데일리 신하연 기자] 세포·유전자치료제(CGT) 전문기업 이엔셀(456070)이 샤르코-마리-투스병 1A형(CMT1A) 치료제 후보물질 ‘EN001’의 임상 2a상에 속도를 내고 있다. 이엔셀은 EN001의 임상 2a상이 다기관 동시 투여 단계에 본격 진입했다고 8일 밝혔다. 왼쪽 삼성서울병원(추승호 교수, 최병옥 교수, 장종욱 이엔셀 대표), 가운데 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results